AstraZeneca has halted a £200m expansion of its Cambridge research site, part of a £650m UK investment plan.
The project was expected to create 1,000 jobs, but follows the scrapping of a £450m facility in Merseyside.
A company spokesperson confirmed the pause, saying AstraZeneca continually reassesses its investment needs.
While UK plans stall, AstraZeneca pledged $50bn US investment by 2030, including new facilities in multiple states.
The pause caps a week of bad news for UK pharmaceuticals, including Merck cancelling a £1bn London research hub.
Industry leaders warn major companies may stop investing in Britain without stronger government support.
Sanofi and Eli Lilly also paused UK projects, citing an uncompetitive life sciences environment.
The sector disputes NHS drug pricing policies, pressing for a lower clawback rate to match other European markets.
AstraZeneca Pauses £200m Cambridge Expansion as UK Pharma Faces Setbacks
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment